BioVersys AG (XSWX:BIOV) Long-Term Debt: CHF21.28 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF27.00
View Full Analysis

What is BioVersys AG Long-Term Debt?

BioVersys AG XSWX:BIOV -1.82% 4 Long-Term Debt is CHF21.28 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's Long-Term Debt for the quarter that ended in Dec. 2025 was CHF21.28 Mil.

BioVersys AG's quarterly Long-Term Debt increased from Dec. 2024 (CHF13.63 Mil) to Jun. 2025 (CHF13.99 Mil) and increased from Jun. 2025 (CHF13.99 Mil) to Dec. 2025 (CHF21.28 Mil).

BioVersys AG's annual Long-Term Debt increased from . 20 (CHF0.00 Mil) to Dec. 2024 (CHF13.63 Mil) and increased from Dec. 2024 (CHF13.63 Mil) to Dec. 2025 (CHF21.28 Mil).

BioVersys AG  (XSWX:BIOV) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BioVersys AG Long-Term Debt Related Terms

BioVersys AG Long-Term Debt Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Long-Term Debt Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Long-Term Debt
13.63 21.28

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Long-Term Debt 0.00 13.63 13.99 21.28
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of CHF21.28 Mil mean?
BioVersys AG (XSWX:BIOV) has a Long-Term Debt of CHF21.28 Mil as of Dec. 2025.
Is BioVersys AG's Long-Term Debt too high?
BioVersys AG's current Long-Term Debt is CHF21.28 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Long-Term Debt compare to VRTX and REGN?
BioVersys AG's Long-Term Debt of CHF21.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. BioVersys AG's current Long-Term Debt is CHF21.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Long-Term Debt of CHF21.28 Mil. The current Long-Term Debt is CHF21.28 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Long-Term Debt is CHF21.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.00
Price